Anne Marie Cook's Net Worth
$2.56 Million
Who is Anne Marie Cook?
Anne Marie Cook has an estimated net worth of $2.56 Million. This is based on reported shares across multiple companies, which include BIOGEN IDEC INC, VIACELL INC, Sage Therapeutics, Inc., and Aegerion Pharmaceuticals, Inc..
SEC CIK
Anne Marie Cook's CIK is 0001320559
Past Insider Trading and Trends
2019 was Anne Marie Cook's most active year for acquiring shares with 5 total transactions. Anne Marie Cook's most active month to acquire stocks was the month of January. 2019 was Anne Marie Cook's most active year for disposing of shares, totalling 4 transactions. Anne Marie Cook's most active month to dispose stocks was the month of April. 2019 saw Anne Marie Cook paying a total of $468,839.00 for 45,840 shares, this is the most they've acquired in one year. In 2019 Anne Marie Cook cashed out on 31,544 shares for a total of $2,628,304.72, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
BIOGEN IDEC INC (BIIB) Snapshot price: $200.5
Acting General Counsel
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
VIACELL INC No price found
General Counsel, SVP
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Sage Therapeutics, Inc. (SAGE) Snapshot price: $7.5
SVP, GC & Secretary
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +59.81% | 9K |
$8.96 | -$40,346.88 | 24.04K |
Aug 5
| |||
Form 4
| +80.76% | 11.25K |
—
|
—
| 25.18K |
Feb 13
| |||
Form 4
| +25.95% | 2.83K |
$19.27 | -$22,622.98 | 13.72K |
Nov 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 13
| |||
Form 4
| +21.67% | 1.87K |
$44.16 | -$43,276.80 | 10.5K |
Feb 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 11
| |||
Form 4
| +51.52% | 2.68K |
$40.29 | -$44,963.64 | 7.89K |
Oct 19
| |||
Form 4
| +134.91% | 2.86K |
$58.80 | -$67,267.20 | 4.97K |
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 12
| |||
Form 4
| +150.86% | 1.06K |
$161.38 | -$136,204.72 | 1.76K |
Jul 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 21
| |||
Form 4
|
∞
| 700 |
$98.00 | -$2,023,261.00 | 700 |
Scheduled
|
May 10
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Aegerion Pharmaceuticals, Inc. No price found
SVP, General Counsel
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |